Age-Related Macular Degeneration Epidemiology Analysis and Forecast, 2021-2031

Age-Related Macular Degeneration Epidemiology Analysis and Forecast, 2021-2031

Summary

Age-related macular degeneration (AMD) is a progressive eye condition that is characterized by the gradual deterioration of the macula, which is the area of the retina responsible for central vision. AMD is the most common cause of significant irreversible vision loss among the elderly (National Eye Institution, 2019). AMD is classified into three stages: early AMD, intermediate AMD, and late AMD. Late AMD is the advanced stage of AMD, which is characterized by the presence of late dry AMD or late wet AMD (van Leeuwen, 2003; Coleman et al., 2008; Korb et al., 2014). According to a meta-analysis study, the pooled prevalence of any AMD was reported to be 8.69% among adults ages 45-85 years, but the country-specific total prevalence of AMD can be as high as 30-40% (Augood et al., 2006; Wong et al., 2014). In addition to the high prevalence of the condition, AMD is also associated with severe disability and has a major impact on the quality of life and emotional well-being of an affected individual (Hassell, 2006).

In 2021, there were 79,030,963 total prevalent cases of AMD in men and women combined, age 50 years and older, in the 7MM. Japan accounted for the majority of these cases with 15,936,633 total prevalent cases, while Spain accounted for the fewest cases with 7,002,545 cases in 2021. GlobalData epidemiologists forecast an increase in the total prevalent cases of AMD to 88,512,609 cases in 2031 in the 7MM at an Annual Growth Rate (AGR) of 1.20% during the forecast period. In 2021, there were 33,658,984 diagnosed prevalent cases of AMD in men and women combined, age 50 years and older, in the 7MM. Italy accounted for the majority of these cases with 6,937,268 cases, while Spain accounted for the fewest cases with 2,680,994 cases in 2021. The diagnosed prevalent cases of AMD will increase to 40,317,447 cases in 2031 at an AGR of 1.98% during the forecast period.

Scope

• This report provides an overview of the risk factors, comorbidities, and the global and historical trends for AMD in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
• The report also includes a 10-year epidemiological forecast for the total prevalent cases and diagnosed prevalent cases of AMD, each segmented into early AMD and late AMD and broken down by sex and age (50-59 years, 60-69 years, 70-79 years, and 80 years and older). The total and diagnosed prevalent cases of late AMD are further segmented into late dry AMD and late wet AMD. The report also includes the total prevalent cases and diagnosed prevalent cases of geographic atrophy (GA) in these markets. The forecast is supported by robust, country-specific data that was obtained from various authentic sources such as research articles published in peer-reviewed journals. In addition, in the case of data scarcity, GlobalData epidemiologists used primary market research (PMR) data wherever necessary.
• The AMD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
• The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

• Develop business strategies by understanding the trends shaping and driving the global AMD market.
• Quantify patient populations in the global AMD market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the age groups that present the best opportunities for AMD therapeutics in each of the markets covered.
• Understand magnitude of AMD by early AMD and late AMD. Late AMD are further segmented into late dry AMD and late wet AMD.